Advanced prostate cancer research focuses on newer agents for mCRPC
Research in advanced prostate cancer is largely focused on newer agents for metastatic castration-resistant prostate cancer, including abiraterone acetate (ZYTIGA), enzalutamide (XTANDI), radium Ra 223 dichloride (Xofigo), and the immunotherapy sipuleucel-T (Provenge).
This articles is part of the State of Urology 2014
Dr. ThrasherResearch in advanced prostate cancer is largely focused on newer agents for metastatic castration-resistant prostate cancer (mCRPC), including abiraterone acetate (ZYTIGA), enzalutamide (XTANDI), radium Ra 223 dichloride (Xofigo), and the immunotherapy sipuleucel-T (Provenge).
“At this year’s annual meeting, we will hear more about optimal sequencing and use of the new drugs recently approved for mCRPC and get a glimpse at new agents being tested,” said J. Brantley Thrasher, MD, professor and chair of urology at the University of Kansas Medical Center, Kansas City.
Early-stage trials will examine the anti-cancer activity of VT-464, a small molecule CYP17A1 inhibitor, and Prostate Specific Membrane Antigen Antibody Drug Conjugate, a human antibody to PSMA.
Specifically, here are the can't-miss abstracts from this year's AUA annual meeting, as selected by Dr. Thrasher:
PD27-06: Simvastatin and Metformin: A Deadly Combination for Metastatic Castration-Resistant Prostate Cancer
Melissa Babcook
PD27-11: A Phase II, Randomized, Double-blind, Placebo-Controlled Trial of Methylphenidate for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH-Agonist Therapy
Patrick O. Richard
PD27-12: Biochemical efficacy of Enzalutamide in post-chemo mCRPC patients previously treated with Abiraterone
M. Andreas Røder
MP70-02: Treatment practice patterns in metastatic castration-resistant prostate cancer patients prior to receiving sipuleucel-T: Data from PROCEED
Matthew Cooperberg
MP70-05: Anti-cancer activity of the selective CYP17A1 inhibitor, VT-464, in pre-clinical models of castrate-resistant prostate cancer
Paul Toren
MP70-10: Further Characterization of the Effects of Prior or No Prior Docetaxel Therapy on CRPC Patients With Bone Metastases Receiving Ra-223 in the Phase 3 ALSYMPCA Trial
Neal Shore
MP70-13: Impact of Screening and treatment pattern on Racial and Ethnic Differences in Outcomes among Advanced Stage Prostate Cancer Patients
Sumedha Chhatre
MP70-18: Mortality in men with advanced prostate cancer may be reduced with radical treatment compared to androgen deprivation alone
Prasanna Sooriakumaran
MP70-20: A Phase 2 trial of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in Taxane-Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Daniel Petrylak
Subscribe to Urology Times to get monthly news from the leading news source for urologists.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
